Cited 6 times in
Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 엄재선 | - |
dc.contributor.author | 원호연 | - |
dc.contributor.author | 이문형 | - |
dc.contributor.author | 정보영 | - |
dc.contributor.author | 박희남 | - |
dc.date.accessioned | 2015-01-06T17:12:20Z | - |
dc.date.available | 2015-01-06T17:12:20Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99532 | - |
dc.description.abstract | PURPOSE: Although current guidelines recommend continuing the same antithrombotic strategy regardless of rhythm control after radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF), anticoagulation has a risk of major bleeding. We evaluated the safety of switching warfarin to aspirin in patients with successful AF ablation. MATERIALS AND METHODS: Among 721 patients who underwent RFCA of AF, 608 patients (age, 57.3±10.9 years; 77.0% male, 75.5% paroxysmal AF) who had no evidence of AF recurrence at 3 months post-RFCA were included. We compared the thromboembolic and hemorrhagic events in patients for whom warfarin was switched to aspirin (ASA group; n=296) and patients who were kept on warfarin therapy (W group; n=312). RESULTS: There were no significant differences in CHA₂DS₂-VASc or HAS-BLED scores between the groups. In 30 patients in the ASA group and 37 patients in W group, AF recurred and warfarin was restarted or maintained during the 18.0±12.2 months of follow-up. There were no significant differences in thromboembolic (0.3% vs. 1.0%, p=0.342) and major bleeding incidences (0.7% vs. 0.6%, p=0.958) between ASA and W groups during the follow-up period. In the 259 patients with a CHA₂DS₂-VASc score≥2, there were no significant differences in thromboembolism (0.8% and 2.2%, p=0.380) or major bleeding incidences (0.8% and 1.4%, p=0.640) between ASA and W groups. CONCLUSION: Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA₂DS₂-VASc score≥2. However, strict rhythm monitoring cannot be overemphasized. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1238~1245 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anticoagulants/therapeutic use* | - |
dc.subject.MESH | Aspirin/administration & dosage | - |
dc.subject.MESH | Aspirin/therapeutic use* | - |
dc.subject.MESH | Atrial Fibrillation/surgery* | - |
dc.subject.MESH | Catheter Ablation | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hemorrhage/epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Postoperative Complications/epidemiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Thromboembolism/epidemiology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Warfarin/administration & dosage | - |
dc.subject.MESH | Warfarin/therapeutic use* | - |
dc.title | Safety and efficacy of switching anticoagulation to aspirin three months after successful radiofrequency catheter ablation of atrial fibrillation. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jae-Sun Uhm | - |
dc.contributor.googleauthor | Hoyoun Won | - |
dc.contributor.googleauthor | Boyoung Joung | - |
dc.contributor.googleauthor | Gi-Byoung Nam | - |
dc.contributor.googleauthor | Kee-Joon Choi | - |
dc.contributor.googleauthor | Moon-Hyoung Lee | - |
dc.contributor.googleauthor | You-Ho Kim | - |
dc.contributor.googleauthor | Hui-Nam Pak | - |
dc.identifier.doi | 10.3349/ymj.2014.55.5.1238 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02337 | - |
dc.contributor.localId | A02448 | - |
dc.contributor.localId | A02766 | - |
dc.contributor.localId | A03609 | - |
dc.contributor.localId | A01776 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 25048480 | - |
dc.subject.keyword | Anticoagulation | - |
dc.subject.keyword | aspirin | - |
dc.subject.keyword | atrial fibrillation | - |
dc.subject.keyword | catheter ablation | - |
dc.contributor.alternativeName | Uhm, Jae Sun | - |
dc.contributor.alternativeName | Won, Ho Youn | - |
dc.contributor.alternativeName | Lee, Moon Hyoung | - |
dc.contributor.alternativeName | Joung, Bo Young | - |
dc.contributor.alternativeName | Pak, Hui Nam | - |
dc.contributor.affiliatedAuthor | Uhm, Jae Sun | - |
dc.contributor.affiliatedAuthor | Won, Ho Youn | - |
dc.contributor.affiliatedAuthor | Lee, Moon Hyoung | - |
dc.contributor.affiliatedAuthor | Joung, Bo Young | - |
dc.contributor.affiliatedAuthor | Pak, Hui Nam | - |
dc.citation.volume | 55 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1238 | - |
dc.citation.endPage | 1245 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.55(5) : 1238-1245, 2014 | - |
dc.identifier.rimsid | 39482 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.